Clarivate

DECEMBER 6, 2022

healthcare provision landscape, integrated delivery networks, or IDNs, are differentiating their offerings by adding outpatient treatment centers, pursuing National Cancer Institute designations and investing in value-based care. Christopher Silva, Senior Healthcare Research Analyst. Pillo, Senior Healthcare Research Analyst.

Networking 52

Networking Healthcare Healthcare Competition 52

European Pharmaceutical Review

APRIL 30, 2024

What are the top three trends that you are seeing in the biopharma manufacturing space? Let’s talk about continuous biopharma manufacturing. Speaking of your biopharma clients, what are you hearing about their main priorities? I believe this is going to be an emerging trend in the market.

Manufacturing 79

Manufacturing Food and Drug Administration Biopharma Marketing 79

Clarivate

MAY 8, 2024

As companies face the prospect of major revenue challenges over the next few years, securing inorganic growth through strategic alliances is increasingly attractive. As a result, 2023 saw an upsurge in merger and acquisition (M&A) and deal activity.

Pharma 59

Pharma Biopharma Prospecting Competition 59

Clarivate

DECEMBER 14, 2023

Here are a few trends in life sciences and healthcare our analysts are keeping an eye on – and what they expect to see in 2024: Move over, oncology – metabolic drugs are the new hotness: The successful launches of Novo Nordisk’s Wegovy® and Eli Lilly’s Mounjaro® represent a revolutionary pharmacological breakthrough of rare proportions.

Pharma 111

Pharma Pharmacology Government Healthcare 111

Clarivate

FEBRUARY 28, 2023

Using real world data to analyze LHON dynamics To better understand the dynamics of LHON, including disease prevalence and drug usage in the United States, we analyzed real world data from electronic health records (EHR), claims and pharmacy data from healthcare institutions and providers. The Clarivate U.S. ” Cureus; V.12;

Prescription 98

Prescription Patients Pharmacology Healthcare 98

Clarivate

OCTOBER 7, 2021

As part of our Drugs to Watch series, which reviews therapies expected to have significant impact on healthcare markets, Clarivate oncology experts sifted through the more than 2,800 abstracts that were accepted for presentation at the ESMO 2021 Virtual Conference and selected their top picks. Abstract LBA52. Abstract 944P.

Patients 91

Patients Safety Marketing Physicians 91

Pharmaceutical Technology

MARCH 21, 2023

Vetter Pharma-Fertigung GmbH & Co KG is contracted for the parenteral manufacture and packaging for the vascular endothelial growth factor (VEGF) inhibitor, while Biogen and KBI Biopharma are producing the biologic API. Baxter Biopharma Solutions is contracted for the parenteral manufacture and packaging of Enhertu.

Manufacturing 59

Manufacturing Pharmaceutical Biopharma FDA 59

Pharmaceutical Technology

MAY 3, 2023

“The proposed facility would play a vital role in fulfilling demand in the Asia Pacific region while representing an important hub for further biopharma industry development in South Korea.” Merck is a science and technology firm with operations across life science, healthcare and the electronics industries.

Government 52

Government Electronics Biopharma Prospecting 52

Pharmaceutical Technology

JANUARY 15, 2023

On November 30, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) awarded a Great Britain marketing authorization to Aurinia Pharmaceuticals’ Lupkynis (voclosporin) for the treatment of lupus nephritis. Seagen has contracted the antibody drug conjugate’s (ADC) manufacturing to several companies.

Manufacturing 52

Manufacturing Pharmaceutical FDA Pharma 52